Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires

Learn more about:
Related Clinical Trial
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires

Brief Summary

      A longitudinal study on immune responses in relation to protection against clinical malaria
      episodes will be conducted in Apac District, Uganda. Three cohorts will be recruited:
      children 1 to 5 years of age (n=250), children 6 to 10 years of age (n=125) and adults 25 and
      above (n=125). After finger prick sampling (~300µL) and examination at enrolment,
      participants will be followed up for one year. Follow-up will include fortnightly active case
      detection and three-monthly cross-sectional surveys. Clinical malaria attacks and the
      associated clinical and parasitological parameters will be related to immunological profiles
      determined utilizing a protein microarray as a capture substratum to profile the humoral
      immune response against a vast number of parasite antigens.

      For individuals who experience a clinical malaria attack or who are diagnosed with high
      density parasitaemia (≥15,000 parasites/µL) during cross-sectional surveys, a 5mL blood
      sample is obtained to determine the diversity of parasite antigens in the population in
      relation to antigen recognition in the cohort.

Study Type


Primary Outcome

Immune correlates of protection against clinical malaria episodes with plasmodium falciparum

Secondary Outcome

 Geographical patterns in malaria morbidity



Study Arms / Comparison Groups

 Children 1-5 years old


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

August 2010

Completion Date

March 2011

Primary Completion Date

March 2011

Eligibility Criteria

        Inclusion Criteria:

          -  age 1-5 years, 6-10 years or 25 yearsand above

          -  written informed consent must be given

          -  the individual must have been resident of the area since birth or for a minimum period
             of two years

          -  the individual must be willing to submit required information and to participate in
             repeated sampling (total blood volume ~2.5 mL over a period of 12 months)

          -  Absence of danger signs (as defined by WHO) or clinical features of AIDS. An HIV-test
             will be offered to all participants at enrolment and completion of the study.

        Exclusion Criteria:

          -  unwillingness to sign consent form

          -  unwillingness to reside in the study area during the follow-up period




1 Year - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers


, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Study Sponsor

Radboud University


 London School of Hygiene and Tropical Medicine

Study Sponsor

, , 

Verification Date

August 2010